SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios latest earnings beat and raised full-year outlook were overshadowed by softer fourth-quarter organic-growth guidance, signaling a slowdown from the prior quarter. Traders are debating whether the selloff is an overreaction to the outlook or a justified repricing for decelerating growth and weaker customer expansion.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Investors are focused on Revolution Medicines upcoming quarterly update for the first full quarter of RASONQUE sales, especially whether new-patient starts show an accelerating launch ramp. Traders are weighing the drugs clinical success and broader pipeline against questions about commercial uptake, competition, and the stocks recent volatility.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is pulling back alongside weakness in cybersecurity and technology stocks, while traders also cite put-heavy options activity and circulate unverified claims of a DHS-related data exposure. The planned S&P 500 inclusion is a bullish counterpoint, but discussion questions whether index-related demand can offset sector pressure and valuation concerns.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradynes strong quarterly results are being overshadowed by a selloff as traders question its next-quarter outlook and cite margin pressure, product mix, and competition. Bulls point to AI-driven chip-testing demand, while bearish comments and put-heavy options positioning reflect concern that the growth outlook may not justify the stocks valuation.

Chainlink (LINK) is a cryptocurrency launched in 2017and operates on the Ethereum platform. Chainlink has a current supply of 1,000,000,000 with 748,099,970.42488396 in circulation. The last known price of Chainlink is 11.67852871 USD and is up 2.18 over the last 24 hours. It is currently trading on 2313 active market(s) with $325,834,414.23 traded over the last 24 hours. More information can be found at https://chain.link/.

ChainLink

LINKs sharp rally and elevated trading activity have sparked bullish calls for a breakout, while traders debate whether it can clear resistance or will pull back. Supporters point to Chainlinks institutional and tokenization integrations, while skeptics question whether network adoption will translate into value for the LINK token.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis, has raised concerns about competition for Precigens PAPZIMEOS and prompted a sharp selloff. Traders disagree over the threat, weighing Voceryqs potential to reduce surgeries against PAPZIMEOSs commercial head start and full-approval status, while questioning Inovios reimbursement and launch execution.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,022,365,191.094644 with 95,022,375,662.737444 in circulation. The last known price of TRON is 0.30232528 USD and is down -8.04 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,465,217,312.79 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention for its relatively steady price action and repeated technical-trading discussion, with many posts describing consolidation or a pullback after a rally. Traders are split between viewing the dip as a healthy pause with long-term strength and worrying that TRX is lagging or could fall further.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

TWST is drawing attention after a sharp, high-volume selloff following a steep rally, with traders linking the move to profit-taking and a broader pullback across speculative genomics and biotech stocks rather than a clearly identified company-specific catalyst. The community is split between bearish concerns about valuation and insider selling and bullish claims of short pressure or market manipulation.

Onyxcoin (XCN) is a cryptocurrency launched in 2021and operates on the Ethereum platform. Onyxcoin has a current supply of 53,402,422,627.32441369 with 40,400,796,729.46127832 in circulation. The last known price of Onyxcoin is 0.00378971 USD and is down -1.54 over the last 24 hours. It is currently trading on 205 active market(s) with $5,616,621.35 traded over the last 24 hours. More information can be found at https://onyx.org.

Onyxcoin

Onyxs ecosystem expansionparticularly discussion of a Robinhood Chain testnet bridge involving ETH and tokenized TSLAis drawing attention, with some traders seeing potential in tokenized assets and payments. Others focus on XCNs weakness and volatile spikes, questioning whether the developments are translating into sustained demand.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

TRUMP memecoins steep decline from its launch highs and reported losses among retail holders dominate discussion, with many traders calling it a pump-and-dump while others argue for accumulating or expect a rebound. The debate is closely tied to backlash over Trump and his familys crypto ventures, though claims of a deliberate scam remain traders opinions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Traders are focused on Oculars expected AXPAXLI NDA submission for wet AMD and whether FDA acceptance will start the review clock. Bulls see the filing as a key catalyst, while skeptics argue it may be priced in and point to competitive data and uncertainty about the drugs eventual approval and commercial uptake.

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.read more...

Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus — The Week’s Biotech Watchlist

Equity

Rocket, RegenXBio, Precision BioSciences, Kyverna and uniQure will present on Monday at a cell and gene-therapy conference.

OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD

OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs. 


OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs

OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.  


OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why

EyePoint Pharmaceuticals said on Monday that its late-stage trial of DURAVYU, an experimental long-lasting eye implant for wet age-related macular degeneration, missed its main goal. 

Why Is Ocular Therapeutix Stock Gaining Monday?

Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD treatment Duravyu.read more...

EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate

EyePoint posted the results for its Phase 3 Lugano trial, which compared its Duravyu therapy with Aflibercept, the standard treatment for wet AMD.


Notable Wednesday Option Activity: OCUL, LLY, WEN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ocular Therapeutix Inc (Symbol: OCUL), where a total of 25,374 contracts have traded so far, representing approximately 2.5 million underlying shares. That amounts to ab...

OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights

Ocular’s total cash and cash equivalents stood at $598.6 million at the end of the second quarter, which it expects will provide sufficient cash runway until 2028.


Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of +12.50% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Lilly won FDA approval last week to expand Jaypirca’s use to patients starting treatment for certain blood cancers.</li><li>Ocular will present eye-treatment research between Oct. 8-9 ahead of an upcoming fourth-quarter FDA filing.</li><li>Roche awaits an Oct.9 FDA decision on Tecentriq for certain colon-cancer patients after surgery.</li></ul><p>After Eli Lilly (LLY) secured a new approval for its leukemia drug Jaypirca on Friday, the pharma spotlight turns this week to Roche’s bid to bring immunotherapy into postoperative colon-cancer treatment. Alongside the FDA milestone, Ocular Therapeutix (OCUL) and several gene-therapy developers will present research and program updates at conferences.</p><p>The<a href="https://stocktwits.com/symbol/XLV">&nbsp;Health Care Select Sector SPDR Fund (XLV)</a> fell 2.7% last week, underperforming the broader market’s<a href="https://stocktwits.com/symbol/SPY">&nbsp;SPDR S&amp;P 500 ETF Trust (SPY)</a>, which slipped 0.2%, and the<a href="https://stocktwits.com/symbol/QQQ">&nbsp;Invesco QQQ Trust (QQQ)</a>, which gained 0.7%. The<a href="https://stocktwits.com/symbol/IBB">&nbsp;iShares Biotechnology ETF (IBB)</a> declined 2.1%, while the<a href="https://stocktwits.com/symbol/XBI">&nbsp;SPDR S&amp;P Biotech ETF (XBI)</a> fell 0.4%. Both biotech funds outperformed XLV but lagged SPY and QQQ.&nbsp;</p><p><img src="https://news.stocktwits-cdn.com/healthcare_4a26e46825.png" alt="healthcare.png"></p><p>&nbsp;</p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>Development</td></tr><tr><td>Oct.5-7</td><td>Meeting on the Mesa</td><td>Cell and gene-therapy companies gather in Phoenix for presentations and regulatory discussions.</td></tr><tr><td>Oct.5</td><td>RCKT, RGNX, DTIL, KYTX, QURE</td><td>Rocket, RegenXBio, Precision BioSciences, Kyverna and uniQure have company spotlight presentations.</td></tr><tr><td>Oct.6</td><td>Nanoscope</td><td>Presentation on its retinal gene-therapy program under FDA review.</td></tr><tr><td>Oct.7-10</td><td>NACFC</td><td>The North American Cystic Fibrosis Conference takes place in Atlanta.</td></tr><tr><td>Oct.8-9</td><td>OCUL</td><td>Axpaxli and SOL-1 presentations at ophthalmology events.</td></tr><tr><td>Oct.9</td><td>Roche, FDA</td><td>Target action date for Tecentriq in a defined postoperative colon-cancer population.</td></tr><tr><td>Oct.9,11</td><td>ENTX, ASBMR</td><td>Entera presents Phase 2 analyses of its oral osteoporosis treatment EB613.</td></tr><tr><td>Oct.11-12</td><td>HFSA</td><td>Late-breaking heart-disease presentations extend into the following week.</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>LLY Starts October With Jaypirca Approval</strong></h2><p>Lilly’s latest FDA approval expands Jaypirca’s use to patients starting treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma whose cancer lacks a genetic abnormality known as a 17p deletion.</p><p>The decision was supported by Bruin CLL-313, a randomized study of 282 patients in which Jaypirca reduced the risk of disease progression or death by 80% compared with Bendamustine plus Rituximab, a chemotherapy-based treatment.</p><p>Patients receiving the comparator went a median of 33.5 months without their disease worsening. The Jaypirca group had not reached that median by the analysis, meaning more than half remained alive without disease progression.&nbsp;</p><h2 class="st-heading-2"><strong>RCKT, QURE, RGNX Lead Gene-Therapy Watchlist</strong></h2><p>Meeting on the Mesa, an annual industry conference focused on cell and gene therapies, opens on Monday at the Arizona Biltmore in Phoenix and runs through Wednesday. RegenXBio (RGNX), Rocket Pharmaceuticals (RCKT), Precision BioSciences (DTIL), Kyverna Therapeutics (KYTX) and uniQure (QURE) are scheduled to present on Monday.&nbsp;</p><p>Monday’s agenda also features a keynote from Karim Mikhail, director of the FDA center that oversees cell and gene therapies. Bristol Myers Squibb and Kite executives will discuss access to CAR-T treatments, which modify immune cells to fight cancer, while regulators from the U.S., U.K. and Japan will also discuss how cell and gene therapies are evaluated and approved.&nbsp;</p><h2 class="st-heading-2"><strong>OCUL Presents Axpaxli Data Ahead Of FDA Filing</strong></h2><p>Ocular Therapeutix (OCUL) will present research on its experimental eye treatment Axpaxli on Thursday and Friday at events surrounding the American Academy of Ophthalmology meeting.</p><p>The presentations include findings from SOL-1, a Phase 3 trial in wet age-related macular degeneration, a condition in which abnormal blood vessels damage the retina and can cause central vision loss. Ocular has already released the trial’s headline results, with this week’s sessions offering a closer look at the findings ahead of an upcoming FDA application.</p><p>The company plans to file in the fourth quarter using SOL-1’s efficacy and safety results, alongside interim safety data from its separate SOL-R trial. SOL-R is still underway, with headline results expected in the first quarter of 2028.</p><h2 class="st-heading-2"><strong>Roche Awaits Friday’s Colon-Cancer Decision</strong></h2><p>Roche faces an Oct.9 FDA target date for its bid to expand Tecentriq and Tecentriq Hybreza into treatment after surgery for certain patients with stage III colon cancer.</p><p>The application covers use with chemotherapy in patients whose tumors have defects in repairing DNA, known as mismatch-repair deficiency or high microsatellite instability. These features help identify cancers that may respond to immunotherapy.</p><p>The supporting Atomic study enrolled 712 patients. At three years, 86.3% of patients receiving the immunotherapy-containing treatment were alive without cancer recurrence, compared with 76.2% in the control group. The treatment reduced the risk of recurrence or death by 50%.</p><h2 class="st-heading-2"><strong>Entera’s EB613 Joins Weekend Research Lineup</strong></h2><p>Entera Bio (ENTX) will present analyses of its Phase 2 study of EB613, an experimental oral osteoporosis treatment, on Oct.9 and Oct.11 at the American Society for Bone and Mineral Research’s annual meeting.&nbsp;</p><p>Meanwhile, the Heart Failure Society of America’s meeting brings more research updates on Oct.11 and Oct.12. Sunday’s presentations include patient health-status findings from the Cardio-TTRansform study of Eplontersen and Phase 3 Reveal results for an imaging test designed to detect abnormal protein deposits in the heart. Monday features ACACIA-HCM, a trial of Aficamten in patients with an abnormally thickened heart muscle that does not obstruct blood flow.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-musk-teases-spacexsi-trump-si-push-analyst-shares-unusually-cheap/cZDpLwyRB1D">SPCX Stock Climbs Overnight: Musk Teases SpaceXSI After Trump’s SI Push — Analyst Calls Shares ‘Unusually Cheap’&nbsp;</a></p>

SLS stock has surged 614% over the past year. (Photo credit: Getty Images)

iShares Biotechnology ETF

Lilly(Eli) & Co

Roche Holdings AG ADR

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.97
Prev Close	$7.31
Open	$7.27
Dividend Yield	0.00%
50-Day Moving Average	$8.81
Beta	1.53
Avg. Volume	3.17M
PE Ratio	-4.93

52-Week High	$16.44
52-Week Low	$6.00
Market Capitalization	$1.53B
EPS (Annual)	-$1.42
Price to Book	2.94
Revenue Per Employee	$159,849.23

Feed

News

Sentiment

Earnings

Fundamentals

Info

OCUL Fundamentals